Talk:Bispecific monoclonal antibody

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 27 September 2021 and 3 December 2021. Further details are available on the course page. Student editor(s): Yutong Wu. Peer reviewers: Yuqingli1015, Cocomonster0o.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 18:05, 17 January 2022 (UTC)[reply]

Wiki Education Foundation-supported course assignment

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Immcarle32.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 15:51, 16 January 2022 (UTC)[reply]

Production of bispecific mabs

I removed the following text from the article because I couldn't fix the grammar:

By using Recombinant DNA technique to combine two different lines of myeloid cells to produce Hybri-Hybridoma. Each Myeloid cell line is capable of producing its respective antibody. This engineered antibody consists of 2 different Fab portions and a consistent Fc portion. The two different Fab portions enables this antibody to bind to two targeted cells and/or protein particles with 2 different receptors.

Can someone get this straight? It would probably be better, though, to translate the corresponding section from de: --ἀνυπόδητος (talk) 20:15, 23 October 2009 (UTC)[reply]

Never mind. This (more or less) describes the production of a trifunctional antibody, which is already covered there. --ἀνυπόδητος (talk) 16:07, 17 January 2010 (UTC)[reply]

Should this cover trivalent bispecific antibodies

(E1)-3s is described as a trivalent bispecific antibody eg in Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α. - not sure if it should be covered here or possibly in trifunctional antibody. - Rod57 (talk) 00:15, 22 March 2016 (UTC)[reply]

I'd say it belongs in the broader category of Bispecific monoclonal antibody. It fits the BsMAb definition, but it doesn't look like a trifunctional antibody since it hasn't got an Fc region, and it doesn't look like any of the other BsMAb subtypes we have covered on WP. --ἀνυπόδητος (talk) 07:22, 22 March 2016 (UTC)[reply]

Proposed Additions

Hello,
I'm thinking of using the following articles to add some more sections to this article to round out the use of bispecific antibodies in different applications (such as Ebola vaccines) in addition to adding some newer references to the current information. What do you all think of these articles?
-Wec, Anna Z.; Nyakatura, Elisabeth K.; Herbert, Andrew S.; Howell, Katie A.; Holtsberg, Frederick W.; Bakken, Russell R.; Mittler, Eva; Christin, John R.; Shulenin, Sergey (2016-10-21). "A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses". Science. 354 (6310): 350–354. doi:10.1126/science.aag3267. ISSN 0036-8075. PMID 27608667.
-Yang, Fa; Wen, Weihong; Qin, Weijun (2016-12-28). "Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies". International Journal of Molecular Sciences. 18 (1): 48. doi:10.3390/ijms18010048.
-Jaworski, Juan Pablo; Vendrell, Alejandrina; Chiavenna, Sebastián Matias (2017-01-01). "Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success". HIV and AIDS: 661. doi:10.3389/fimmu.2016.00661. PMC PMC5225137Freely accessible Check |pmc= value (help). PMID 28123384.
-Spiess, Christoph; Zhai, Qianting; Carter, Paul J. (2015-10-01). "Alternative molecular formats and therapeutic applications for bispecific antibodies". Molecular Immunology. 67 (2 Pt A): 95–106. doi:10.1016/j.molimm.2015.01.003. ISSN 1872-9142. PMID 25637431.
-Zhukovsky, Eugene A; Morse, Richard J; Maus, Marcela V. "Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection". Current Opinion in Immunology. 40: 24–35. doi:10.1016/j.coi.2016.02.006. PMC PMC4884546Freely accessible Check |pmc= value (help). PMID 26963133.
Thanks --Immcarle32 (talk) 06:38, 8 February 2017 (UTC)[reply]

Clinical trials and approvals

Could start a section on clinical trials - eg of CEA-TCB (CD3) phase 1 - CRC ? Could note the target antigens and disease. - Rod57 (talk) 11:26, 30 June 2017 (UTC)[reply]

Bispecific Playgrounds? No, Factory Floors Dimond Sept 2018 says "Three bsAbs have been approved for different therapeutic indications, and over 50 bsAbs are currently in clinical development." and " about 11 technology platforms are currently in extensive use. These include Dual Affinity Re-targeting (DART) (MacroGenics), Bispecific T-cell Engager (BiTE) (Amgen), CrossMAb (Roche), Nanobody (Ablynx), and XmAb (Xencor)." - Rod57 (talk) 17:28, 20 September 2018 (UTC)[reply]